Nucleic Acid Biochemistry Practice Questions

Q: C4, C5, and N7 in the purine ring are derived from which of the following?

Glycine. ***Glycine*** - The entire **glycine molecule** contributes C4, C5, and N7 to the purine ring structure. - This amino acid provides a significant portion of the backbone to the imidazole ring within the purine. *Aspartate* - **Aspartate** contributes N1 to the purine ring. - It does not involve C4, C5, or N7, which are distinct atoms within the purine molecule. *CO₂* - **CO₂** contributes C6 to the purine ring through a carboxylation step. - It is not involved in providing the atoms at positions C4, C5, or N7. *Glutamine* - The nitrogen atoms N3 and N9 in the purine ring are derived from the **amide nitrogen of glutamine**. - Glutamine's contributions are different from the carbons and nitrogen provided by glycine.

Q: What is the end product of purine metabolism in most mammals?

Allantoin. ***Allantoin*** - **Allantoin** is the primary end product of **purine metabolism** in **most mammals** (except humans and higher primates), formed by the oxidation of uric acid by the enzyme **uricase**. - This conversion makes purine waste products more **water-soluble** and easier to excrete via the kidneys. - **Important clinical note:** Humans lack functional uricase, so **uric acid** is the end product in humans; this distinction is why hyperuricemia and gout occur in humans but not in most other mammals. *Glycogen* - **Glycogen** is a complex carbohydrate and serves as a primary **energy storage molecule** in animals, derived from glucose metabolism, not purine catabolism. - Its metabolism is regulated by hormones like **insulin** and **glucagon**, involved in maintaining blood glucose levels. *Pyrimidine* - **Pyrimidine** is a type of nitrogenous base, structurally distinct from purines, and is a component of DNA and RNA, not an end product of purine catabolism. - **Pyrimidine metabolism** involves the synthesis and breakdown of bases like cytosine, thymine, and uracil, which follows a separate biochemical pathway. *Histidine* - **Histidine** is an **essential amino acid**, a building block of proteins, and is involved in various metabolic processes, including histamine synthesis. - It plays no role as an end product of purine degradation; rather, its own metabolism leads to products like **urocanic acid**.

Q: Which of the following statements is true regarding the sigma factor?

It is a subunit of RNA polymerase.. ***It is a subunit of RNA polymerase.*** - The **sigma factor** is a crucial component of **bacterial RNA polymerase**, guiding it to specific promoter regions on the DNA. - It plays a vital role in **initiation of transcription** by recognizing and binding to the **-10 and -35 boxes** of the promoter. *It is a subunit of DNA polymerase.* - **DNA polymerase** is primarily involved in **DNA replication and repair**, not transcription. - Its subunits, such as the **beta clamp** or **alpha subunit**, are distinct from the sigma factor. *It initiates DNA replication.* - **DNA replication** is initiated by **DNA helicases** unwinding the double helix and **primase** synthesizing RNA primers. - The sigma factor's role is in **transcription**, the synthesis of RNA from a DNA template. *It is a subunit of the 50s ribosome.* - The **50S ribosomal subunit** is a component of the **ribosome**, responsible for **peptide bond formation** during translation. - Its subunits are ribosomal proteins and ribosomal RNA molecules, not the sigma factor.

Q: The gaps between Okazaki fragments on the lagging strand during DNA replication are rejoined and sealed by:

DNA Ligase. ***DNA Ligase*** - **DNA ligase** forms a **phosphodiester bond** between the **3'-OH group** of one Okazaki fragment and the **5'-phosphate group** of the adjacent fragment, effectively sealing the nicks. - After **DNA polymerase I** removes the **RNA primers** and fills in the gaps, DNA ligase completes the synthesis of the **lagging strand** during DNA replication. - This enzyme is essential for maintaining the **integrity of the DNA backbone**. *DNA Helicase* - **DNA helicase** functions to **unwind the DNA double helix**, separating the two strands to create a replication fork. - It does not participate in joining DNA fragments. *DNA Phosphorylase* - **DNA phosphorylase** is not a standard enzyme involved in the direct sealing of DNA fragments during replication. - This is not the enzyme responsible for ligating Okazaki fragments. *DNA Topoisomerase* - **DNA topoisomerase** relieves the **supercoiling tension** that builds up in the DNA double helix ahead of the replication fork due to unwinding. - It does not have a role in forming phosphodiester bonds between newly synthesized DNA fragments.

Q: What is the first purine nucleotide synthesized in de novo purine biosynthesis?

IMP. ***IMP (Inosine Monophosphate)*** - **IMP** is the first complete purine nucleotide synthesized during the **de novo purine biosynthesis pathway**. - It serves as a branch point, from which **AMP** and **GMP** are subsequently synthesized through separate pathways. *AMP (Adenosine Monophosphate)* - **AMP** is a derivative of **IMP**, synthesized by the addition of an amino group from **aspartate** to IMP. - This step occurs after the formation of the complete purine ring structure in IMP. *GMP (Guanosine Monophosphate)* - **GMP** is also derived from **IMP**, through a pathway involving the oxidation of IMP to **XMP** (xanthosine monophosphate) and subsequent amination. - Its synthesis occurs downstream from IMP. *UMP (Uridine Monophosphate)* - **UMP** is a **pyrimidine nucleotide**, not a purine, and is synthesized via a completely different de novo pathway. - Pyrimidine biosynthesis involves forming the ring structure first, then attaching it to ribose-phosphate, unlike purine synthesis which builds the ring on a pre-existing ribose-phosphate.

Q: What are Okazaki fragments?

Short pieces of DNA on the lagging strand.. ***Short pieces of DNA on the lagging strand.*** - **Okazaki fragments** are the short, newly synthesized DNA fragments that are formed on the **lagging strand** during DNA replication. - The lagging strand is synthesized discontinuously because DNA polymerase can only add nucleotides in the **5' to 3' direction**, requiring it to move away from the replication fork as the DNA unwinds. *Long pieces of DNA on the lagging strand.* - The lagging strand is synthesized discontinuously in **short fragments**, not long continuous pieces. - The enzyme **DNA ligase** eventually joins these short fragments together to form a continuous strand. *Short pieces of DNA on the leading strand.* - The **leading strand** is synthesized continuously in one long stretch, moving towards the replication fork. - It does not require the synthesis of short fragments like the lagging strand. *Long pieces of DNA on the leading strand.* - While the leading strand is synthesized in a continuous, long piece, this statement does not accurately describe Okazaki fragments, which are specific to the lagging strand. - The leading strand's continuous synthesis is due to its **3' to 5' template orientation**, allowing DNA polymerase to proceed uninterrupted.

Q: Rate limiting step in pyrimidine synthesis?

Carbamoyl phosphate synthase-II. ***Carbamoyl phosphate synthetase II (CPS-II)*** - **CPS-II** is the **committed and rate-limiting enzyme** in **de novo pyrimidine synthesis** in **mammals (including humans)** - It catalyzes the formation of **carbamoyl phosphate** from glutamine, CO₂, and 2 ATP in the **cytoplasm** - This is the **first committed step** and the main **regulatory checkpoint**, inhibited by UTP (feedback inhibition) and activated by PRPP and ATP - CPS-II is part of the **CAD complex** (carbamoyl phosphate synthetase, aspartate transcarbamoylase, dihydroorotase) in mammals *Aspartate transcarbamoylase (ATCase)* - ATCase catalyzes the **second step**: condensation of carbamoyl phosphate with aspartate to form carbamoyl aspartate - While ATCase is the **rate-limiting step in bacteria** (E. coli), in **mammals** it is part of the CAD complex and **not the primary regulatory step** - This option is incorrect for human/mammalian biochemistry tested in NEET PG *Dihydro-orotase* - The **third enzyme** in the pathway, converting carbamoyl aspartate to dihydroorotate - Part of the CAD complex in mammals but **not the rate-limiting step** *Dihydroorotate dehydrogenase* - Catalyzes the **fourth step**: oxidation of dihydroorotate to orotate - Located on the **outer surface of the inner mitochondrial membrane** (only mitochondrial enzyme in the pathway) - Important enzyme but **not rate-limiting**

Q: In eukaryotic cells, where does the majority of functional RNA activity occur?

Cytoplasm. ***Cytoplasm*** - The **cytoplasm** is the cellular compartment where the **majority of functional RNA activity** occurs, including **translation** (protein synthesis) involving mRNA, tRNA, and rRNA. - **Ribosomes** (the sites of translation) are located in the cytoplasm, either free-floating or bound to the endoplasmic reticulum. - Many types of **regulatory RNAs** such as microRNAs (miRNAs) and small interfering RNAs (siRNAs) exert their functions in the cytoplasm by targeting mRNAs for degradation or translational repression. - **mRNA degradation** and **RNA interference pathways** primarily operate in the cytoplasm. - The question asks for the broader location rather than the specific molecular machinery, making cytoplasm the most comprehensive answer. *Nucleus* - While RNA is **transcribed** from DNA and **processed** (capping, polyadenylation, splicing) in the nucleus, these are preparatory steps. - The nucleus is primarily the site of **RNA synthesis**, not where most RNA performs its functional roles. - Only a small fraction of functional RNA activity (like rRNA processing in the nucleolus) occurs here compared to the cytoplasm. *Ribosome* - While **ribosomes are the specific sites of translation** and are composed of rRNA and proteins, they represent molecular machinery rather than a cellular location. - Ribosomes themselves are located **within the cytoplasm**, making cytoplasm the more inclusive answer for where RNA activity occurs. - The question asks "where" in terms of cellular compartment, not which molecular complex. *None of the options* - This is incorrect as the cytoplasm is indeed the primary site where the majority of functional RNA activities occur in eukaryotic cells.

Q: Which of the following organs does not primarily utilize the salvage pathway of purine nucleotide synthesis?

Liver. ***Liver*** - The **liver** is capable of both *de novo* synthesis and the salvage pathway of purine nucleotides, but it primarily utilizes the **de novo pathway** due to its high metabolic capacity and central role in biosynthesis for the entire body. - While salvage pathways exist, the liver's robust *de novo* synthesis allows it to readily produce purines from simple precursors, making it less reliant on salvaging pre-formed bases. *Brain* - The **brain** relies heavily on the **salvage pathway** for purine nucleotide synthesis because it has a limited capacity for *de novo* purine synthesis. - This dependency makes the brain particularly vulnerable to deficiencies in salvage enzymes, such as in **Lesch-Nyhan syndrome** where HGPRT deficiency leads to severe neurological dysfunction. *RBC* - **Red blood cells (RBCs)** are anucleated and lack the machinery for *de novo* purine synthesis, making them entirely dependent on the **salvage pathway** to maintain their purine nucleotide pool. - They salvage pre-formed purine bases and nucleosides from the plasma to synthesize necessary adenine and guanine nucleotides. *Leukocytes* - **Leukocytes**, particularly lymphocytes, have a high turn-over rate and metabolic activity, and they primarily rely on the **salvage pathway** for purine nucleotide synthesis. - The **immune system's rapid proliferation** and response demand efficient nucleotide synthesis, and the salvage pathway offers a quick and energy-efficient way to achieve this.

Q: What is the end product of purine metabolism in humans?

Uric acid. ***Uric acid*** - **Uric acid** is the final breakdown product of **purine metabolism** in humans. - It is formed from the degradation of **adenosine** and **guanosine**, with xanthine oxidase playing a key role in its synthesis. *Allantoin* - **Allantoin** is the end product of **purine metabolism** in most mammals other than primates, as they possess the enzyme **uricase** to further break down uric acid. - Humans lack **uricase**, hence allantoin is not the end product in humans. *Carbon Dioxide* - **Carbon dioxide** is a major end product of **carbohydrate** and **fat metabolism** through cellular respiration. - It is not directly associated with the degradation pathway of purines. *None of the options* - This option is incorrect because **uric acid** is indeed the definitive end product of purine metabolism in humans.

Question 1

C4, C5, and N7 in the purine ring are derived from which of the following?

Accepted Answer

Glycine

Answer

CO₂

Answer

Aspartate

Answer

Glutamine

Question 2

What is the end product of purine metabolism in most mammals?

Accepted Answer

Allantoin

Answer

Glycogen

Answer

Pyrimidine

Answer

Histidine

Question 3

Which of the following statements is true regarding the sigma factor?

Accepted Answer

It is a subunit of RNA polymerase.

Answer

It is a subunit of DNA polymerase.

Answer

It initiates DNA replication.

Answer

It is a subunit of the 50s ribosome.

Question 4

The gaps between Okazaki fragments on the lagging strand during DNA replication are rejoined and sealed by:

Accepted Answer

DNA Ligase

Answer

DNA Helicase

Answer

DNA Phosphorylase

Answer

DNA Topoisomerase

Question 5

What is the first purine nucleotide synthesized in de novo purine biosynthesis?

Accepted Answer

IMP

Answer

AMP

Answer

GMP

Answer

UMP

Question 6

What are Okazaki fragments?

Accepted Answer

Short pieces of DNA on the lagging strand.

Answer

Long pieces of DNA on the lagging strand.

Answer

Short pieces of DNA on the leading strand.

Answer

Long pieces of DNA on the leading strand.

Question 7

Rate limiting step in pyrimidine synthesis?

Accepted Answer

Carbamoyl phosphate synthase-II

Answer

Aspartate transcarbamoylase (ATCase)

Answer

Dihydroorotate dehydrogenase

Answer

Dihydro-orotase

Question 8

In eukaryotic cells, where does the majority of functional RNA activity occur?

Accepted Answer

Cytoplasm

Answer

Nucleus

Answer

Ribosome

Answer

None of the options

Question 9

Which of the following organs does not primarily utilize the salvage pathway of purine nucleotide synthesis?

Accepted Answer

Liver

Answer

RBC

Answer

Leukocytes

Answer

Brain

Question 10

What is the end product of purine metabolism in humans?

Accepted Answer

Uric acid

Answer

Carbon Dioxide

Answer

Allantoin

Answer

None of the options

Nucleic Acid Biochemistry — MCQs

Nucleic Acid Biochemistry — MCQs

On this page

Practice by Chapter

Want unlimited practice?